Clinical Trial Update: Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating dasatinib in combination with bortezomib and dexamethasone for multiple myeloma was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Sprycel (dasatinib)
• Velcade (bortezomib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED | Results posted: 2012-07-09